OrbiMed’s Cabaletta Bio CABA Stock Holding History

OrbiMed’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-577,509	Closed	-$1.17M	–	144
2022 Q1	$1.17M	Buy	577,509 +275,000	+91%	+$719K	0.02%	137
2021 Q4	$1.15M	Hold	302,509	–	–	0.01%	155
2021 Q3	$3.68M	Buy	+302,509	New	+$2.79M	0.04%	158

Other funds holding CABA

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

OrbiMed's CABA Position: Q2 2022 in Review

OrbiMed sold out of Cabaletta Bio (CABA) in Q2 2022, closing a stake of 577,509 shares — an estimated $1.17M sold.

OrbiMed first reported a position in CABA in Q3 2021 and held it in 3 quarters. The position peaked at $3.68M in Q3 2021. 55 funds tracked by Wall St. Rank hold CABA as of Q2 2022.

OrbiMed reported no remaining Cabaletta Bio position as of Q2 2022 after selling out during the quarter.
OrbiMed sold 577,509 Cabaletta Bio shares in Q2 2022, an estimated $1.17M.
OrbiMed first reported a position in Cabaletta Bio in Q3 2021 and held it in 3 quarters.
OrbiMed's Cabaletta Bio position peaked at $3.68M in Q3 2021.
55 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2022.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.